About us   Products   News archive   Sitemap   Links   Contact us  

    

Hermes Belt Ladies

ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas.

Hermes Belt Ladies

Hermes Belt Ladies

Hermes Belt Ladies

Hermes Belt Ladies

PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX (Marketwire June 30, 2011) Agennix AG (FRANKFURT: AGX) (XETRA: AGX) today announced that the first patient has been dosed in the Phase II part of the OASIS (Oral Talactoferrin in Severe Sepsis) trial, a multicenter, double blind, randomized Phase II/III trial evaluating the oral immunotherapy talactoferrin for the treatment of severe sepsis. "Building on the promising results from our earlier Phase II study with talactoferrin in severe sepsis, the OASIS trial should give us important insight into the potential utility of talactoferrin as a treatment for this major unmet medical need."

Hermes Belt Ladies

evaluate the safety and tolerability of talactoferrin in this patient population, and data will be collected to further elucidate the mechanism of action of talactoferrin. Additional information about the trial can be found at Talactoferrin is an oral immunotherapy that is being studied for the treatment of cancer and severe sepsis. Talactoferrin has demonstrated promising activity in randomized, double blind, placebo controlled Phase II studies in non small cell lung cancer (NSCLC) and in severe sepsis. Two Phase III trials with talactoferrin in NSCLC are ongoing. The FORTIS M trial, which completed enrollment in March 2011, is evaluating talactoferrin in NSCLC patients whose disease has progressed following two or more prior treatment regimens. A second Phase III trial FORTIS C is evaluating talactoferrin in combination with the standard chemotherapy regimen, carboplatin/paclitaxel, in first line NSCLC patients. NSCLC is one of the most common types of cancer worldwide and the most frequent cause of cancer death. Agennix is also developing talactoferrin for the treatment of severe sepsis and has initiated a Phase II/III trial, called the OASIS trial, in that indication. The Company's most advanced program is talactoferrin, an oral immunotherapy that has demonstrated activity in randomized, double blind, placebo controlled Phase II studies in non small cell lung cancer and in severe sepsis. Talactoferrin is Hermes Belt Ladies currently in Phase III clinical trials in non small cell lung cancer, and a Phase II/III trial with talactoferrin in severe sepsis is underway. Other clinical development Louis Vuitton Belt No Buckle

programs include RGB 286638, a multi targeted kinase inhibitor in Phase I testing, and a topical gel form of talactoferrin for diabetic foot Gucci Belt Transparent Background

The OASIS trial is evaluating talactoferrin plus standard care compared to placebo plus standard care in adult patients with severe sepsis. The Phase II part of the trial is planned to enroll approximately 350 patients at clinical sites predominantly in Western Europe and North America. The study's primary objective is to determine the effect of talactoferrin on 28 day all cause mortality. Secondary endpoints include three month, six month and twelve month all cause mortality. The study will also Gucci Belts

Agennix AG Initiates Phase II III OASIS Trial With Talactoferrin in Severe Sepsis

Hermes Belt Ladies

Hermes Belt Ladies

Hermes Belt Ladies

Hermes Belt Ladies

Hermes Belt Ladies

Hermes Belt Ladies

Gucci Belt Heart

Michael Kors Marina Grab Bag
Michael Kors Crossbody Jet Set Large
Lv Belt 2018

Hermes Belt New

Gucci Belt With Tiger Buckle

Versace Belt Buckle

Michael Kors Grayson Satchel
Gucci Belt With Stars

Gucci Belt Buckle Only

Hermes Belt White

Gucci Belt

Gucci Belt No Buckle

Michael Kors Crossbody Studded Purse
Michael Kors Hamilton Purple

Home / Hermes Belt Ladies